TELA logo

TELA BIO INC

TELANASDAQ
🏆 #4410 by market capUS Equity
$799.72▲ $26.95 (+3.37%)
Simulated price
🔔
Track TELA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$55M
Small Cap
📈Revenue Growth (YoY)
+15.8%
Healthy
📊Gross Margin
67.8%
High
💵FCF Margin
-39.6%
Thin
⚖️P/S Ratio
0.7x
Cheap
Otter Score
80
Good
No chart data available for TELA.

Trading Snapshot

Day Range
$795.25 – $815.07
52-Week Range
$0.50 – $1.60
Volume
$2.96B
Avg Volume
$2.43B
Shares Outstanding
44.7M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$80M
Last Q Revenue
$19M
P/E Ratio
-1.6
P/S Ratio
0.7x
EPS (TTM)
$-0.72
Dividend Yield
0.00%
Dilution (1yr)
+29.0%

Why Investors Own TELA

  • ✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 65% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TELA logo

TELA BIO INC

TELA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$80M▲ +15.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.7%▲ +0.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$34M▼ −1.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$29M▼ −32.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.7M▲ +29.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$5M▼ −$14M YoY
StockOtter · stockotter.space

About TELA BIO INC

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$869.15
▲ +8.7% Upside
High Target$1,084.38
Low Target$798.16
Based on 11 analysts

Latest News & Updates

🚀
CNBC·2h ago

TELA BIO INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift TELA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

TELA BIO INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.